Nurix Therapeutics (NRIX) EBITDA (2019 - 2026)
Nurix Therapeutics (NRIX) EBITDA from Feb 28, 2019 to May 31, 2026. The TTM Nurix Therapeutics (NRIX) EBITDA is -$354M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Nurix Therapeutics (NRIX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +61.36% |
| 3 Years TTM | +30.88% |
| 5 Years TTM | +32.18% |
| All Time TTM | +62.19% |
Annual EBITDA change of Nurix Therapeutics (NRIX)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$180M | -34.96% |
| 2025 | -$277M | +35.94% |
| 2024 | -$204M | +38.08% |
| 2023 | -$148M | -17.36% |
| 2022 | -$179M | +55.10% |
| 2021 | -$115M | +83.28% |
| 2020 | -$63M | +215.90% |
| 2019 | -$20M | N/A |
Comparison Nurix Therapeutics (NRIX) five years EBITDA CAGR with competitors
Nurix Therapeutics (NRIX) five years EBITDA CAGR is 32.18%.